Abstract
Introduction
hrs and Palmitic Acid (PA) at 100, 500 and 750 μM for 24 hr. At the end of the treatment 160 period, podocytes were lysed in Tryzol for downstream analysis of gene expression. When 161 podocytes were used for protein detection by western blotting, they were homogenized in 162 lysis buffer containing a protease and phosphatase inhibitor cocktail.
163
Immunodetection of B7-1 in human podocytes (Western blotting) 164 For each sample, 25 ug total protein was resolved by electrophoresis using 4-20% 165 precast polyacrylamide gels under denaturing conditions. Proteins were transferred to following Li-Cor PBS protocol. Imaging was carried out using Odyssey technology (Li-Cor).
170
Fluorescent detection was performed after incubating with the corresponding secondary Novus Biologicals 2E5 catalogue number NBP2-02905. As loading control for cellular 176 homogenates, the anti-human GAPDH antibody from Sigma (catalogue number G9545) was 177 used. As positive control we used recombinant human B7-1 and Rajji and Daudi cell 178 homogenates. As negative controls we used mouse recombinant B7-1 and rat fibroblast 179 homogenates.
180

RNA extraction and quantitative real-time polymerase chain reaction (qPCR).
181
For podocytes, total RNA was extracted using TRI Reagent (Sigma). 1 μg of RNA City, CA, USA). qPCR was performed using the SyBr Green method and d(N)6 random 184 hexamer with the primers for human B7-1 previously reported 17 . RNA B7-1 was expressed 185 relative to β-actin expression.
186
For kidney tissues, total mRNA was extracted using a magnetic bead-based semi-187 automated method (ThermoFisher Scientific). After cDNA synthesis, gene expression
188
(relative to gapdh) was measured using TaqMan probes (Applied Biosystems) and fold 189 change in expression calculated using the ΔΔCt method.
Immunohistochemistry
191
Fixed 3-4 μm sections of mouse and human kidneys were used and staining
192
performed either on the Dako Flatbed autostainer (CD3, F4/80, B7-1) or the Ventana Ultra
193
(Podocyn, WT1, Collagen IV). Analysis was done by using the Aperio ePathology Digital
194
Image Analysis Software, Definiens Tissue Studio or Visiopharm.
195
Immunodetection of B7-1 was performed in 20 human kidney biopsies collected under 196 consent at the Sahlgrenska University in Gothenburg, Sweden (10 DN and 10 controls).
197
Patient characteristics were as follows: 
261
In the STZ-treated group, glomerular filtration rate (GFR) was found increased but (Table 3) . No differences were found in kidney weights at the end of the study 268 (Table 3) .
269
The exposure levels of Abatacept were verified in plasma. In the prevention groups, at 
303
Neither podocyte number nor B7-1 expression was affected in the STZ-induced diabetes 304 animals.
305
We next performed immunostaining for the podocyte-specific proteins WT1 and
306
Podocin at the end of the study (20 weeks after induction of diabetes, prevention arm). As (Table 4) . 
B7-1 (CD80) is not expressed in human kidneys from diabetic nephropathy individuals
334
Finally we conducted immunostaining of human kidneys to investigate expression 
Discussion
351
In this study we found that blocking T-cell activation is sufficient to achieve reduction this model as we did not detect B7-1 mRNA in the mouse kidneys (Fig 3) . Unlike the Abatacept reverses albuminuria experimentally, this treatment has the potential to "slow",
494
and even "stop", renal damage and disease progression in DN patients preventing them from 495 reaching end stage renal disease.
496
In conclusion, we demonstrated that blocking T-cell activation ameliorates 
666
Abatacept had no effect on STZ-induced glomerular hyper-filtration. n= 9-13 per group. (B7-1) and 18 (housekeeping β-actin).
